Poznan

• A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in … Pending
  2025-525127-27-00 9 Generalized Myasthenia Gravis
• Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending
  2026-525263-41-00 5 Hodgkin lymphoma
• A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Recruiting
  2025-523950-15-01 4 2026-05-29 Generalized Myasthenia Gravis
• A Phase 2 Study of JNJ-79635322 in Participants with RRMM Recruiting
  2025-521976-80-00 4 2026-05-28 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting
  2025-522001-38-00 4 2026-05-27 Crohn’s Disease
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri … Recruiting
  2025-523404-74-00 4 2026-05-26 Prurigo Nodularis
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-21 Uncontrolled Moderate to Severe Eosinophilic Asthma
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo … Recruiting
  2025-522093-36-00 10 2026-05-20 Cancer cachexia
• A Study of JNJ-95597528 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Recruiting
  2025-523464-20-00 4 2026-05-20 Moderate to Severe Atopic Dermatitis
• Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting
  2025-522107-18-00 4 2026-05-19 Locally advanced or metastatic Non-Small Cell Lung Cancer
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) Recruiting
  2025-522257-19-00 10 2026-05-12 Relapsing Multiple Sclerosis
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• Phase 2 Study of REGN13335 in Adult Participants with Pulmonary Arterial Hypertension (PAH) Recruiting
  2024-514754-79-00 4 2026-05-06 Pulmonary Arterial Hypertension (PAH)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting
  2025-523742-27-00 9 2026-04-28 Advanced solid tumors
• A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting
  2025-522867-13-00 4 2026-04-27 Non Small Cell Lung Cancer
• A clinical study to test how safe and effective a new inhaled treatment (called L606) is for people with high blood pressure in the lungs du … Recruiting
  2024-517943-29-00 5 2026-04-21 Pulmonary Hypertension associated with interstitial lung disease (WHO
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• Darovasertib before Surgery or Radiation Therapy to Treat Early-stage Eye Cancer (Uveal Melanoma) Recruiting
  2025-522387-32-00 5 2026-04-10 Uveal Melanoma

Showing 49–72 of 914 trials